Healthcare Industry News:  computed tomography 

Regenerative Medicine Personnel

 News Release - March 16, 2006

Medistem Appoints Accomplished Physician and Medical Entrepreneur Roger M. Nocera, MD, as Executive VP and CMO

SCOTTSDALE, Ariz.--(HSMN NewsFeed)--March 16, 2006--Medistem Laboratories, Inc. (OTCBB:MDSM ; FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has named veteran physician and medical entrepreneur, Roger M. Nocera, M.D., as its Executive Vice President and Chief Medical Officer.

Dr. Nocera has had a distinguished career as a physician, scientist and entrepreneur. Dr. Nocera will be responsible for interfacing with Medistem's international affiliate, the Institute for Cellular Medicine, as they spearhead clinical initiatives to realize the full potential of stem cell therapies and commercialize Medistem's proprietary stem cell technologies.

"We are very pleased to welcome Dr. Nocera as our Executive Vice President and Chief Medical Officer," said Neil Riordan, Ph.D., CEO of Medistem. "He is an outstanding, and highly accomplished physician who brings a strong and successful record as a medical entrepreneur," Riordan said. "Significantly, Dr. Nocera is also a medical visionary, who understands the enormous potential of Medistem's proprietary technology to develop ethical, non-controversial adult stem cells. He is the ideal candidate to help our team bring Medistem to the forefront of the potential multibillion dollar marketplace for safe, effective and revolutionary stem cell-sourced therapeutics."

Central among Medistem's business and clinical initiatives is its planned launch of clinical trials to develop stem cell therapies to treat stroke, one of the most widespread causes of disability in the world, and for other neurological conditions, such as Parkinson's and cerebral palsy.

Dr. Nocera is board certified in two separate medical specialties: diagnostic radiology and anti-aging medicine. He founded and remains medical director of Arcadia Radiology & Open MRI, Ltd., in Phoenix, Ariz., and currently also serves as the medical director and owner of the Nocera Antiaging Clinic in Scottsdale, Ariz.

Nocera received his M.D. from the University of Massachusetts Medical School and completed four years of residency training in Diagnostic Radiology at the University of Texas Medical Branch. He also completed a fellowship in computed tomography and Breast Cancer Detection at the UT Medical Branch and a second fellowship in Radiological Pathology at the famed Armed Forces Institute of Pathology, Washington, D.C.

"I'm very pleased to join Medistem as its medical director and to have this opportunity to oversee the advancement of potentially transformative stem cell technologies," said Dr. Nocera. "We are entering a very exciting time in the history of medicine. It is my belief and hope that the development of stem cell therapies will in the near future revolutionize medical therapy in much the same way as the development of antibiotics did in the early twentieth century. We at Medistem are thrilled to be poised to play a role in what we believe may bring hope and enormous medical benefit to millions of patients worldwide who currently have or will have one of the devastating neurological diseases such as stroke and other disorders which are currently incurable," stated Dr. Nocera.

As previously announced, Medistem recently executed a technology licensing and royalty agreement with the Institute for Cellular Medicine (ICM) in San Jose, Costa Rica, which enables ICM to perform clinical programs to further develop Medistem's stem cell technologies and therapies and to treat patients on a fee-for-service basis at ICM's laboratory and clinic facility.

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications ultimately will be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/medistem/quote.html. Medistem is traded on the Frankfurt, Germany, stock exchange under the symbol S2U.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.


Source: Medistem Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.